Markers of Inflammatory Bowel Disease Severity

Overview

About this study

The purpose of this study is to identify blood cell-specific DNA methylation and micro RNA markers in tissue and stool samples in patients wiht inflammatory bowel disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria (apply to Aim 3, subject population #4 only):

Moderate to severely active ulcerative colitis (defined by Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score of ≥2)
Able to provide informed consent;
Scheduled for disease severity assessment by endoscopy (colonoscopy or flexible sigmoidoscopy)
Intended to return to our center for follow-up colonoscopic assessment of response to therapy
Adjunctive medication may be administered; these include, corticosteroids, thiopurine immunomodulators, methotrexate, 5-aminosalicylate therapies
Baseline endoscopy is negative for colorectal cancer or dysplasia

Exclusion Criteria:

Patient has known primary aerodigestive cancer outside of the colon within the last 5 years
Prior colonic resection
Prior colonic neoplasia
Diagnosis of FAP
Diagnosis of Lynch
Participation in another clinical trial of novel IBD therapeutic agent
Use of off-label therapy

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator John Kisiel, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

John Kisiel, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials